- NewsCategory：
- All Company news Industry news
common83One result
-
1017
WindMIL Therapeutics and Univers♠ity of California, Irvine Announcε"&e Collaboration to Collecφ≠♣"t Bone Marrow from Patients with Gliomas
WindMIL Therapeutics and University of Californi♠>∏a, Irvine Announce Collaboration to Collect≈" Bone Marrow from Patie∏§₽nts with GliomasWEDNESDAΩ♦Y, OCTOBER 16, 2019WindMIL TheraΩδpeutics and the University of California, Irvine☆∑γ (UCI) today announced that the first patients ha∞∞ve been identified in an investigator-sponsor≤σΩed study for the collection of bone marrow f♠λ₹rom patients with gliomas. The ÷✔study will evaluate generating marrow infil←↑♥↑trating lymphocytes (MILs™) for these'¥ patients through WindMIL’s propri<>etary cellular activ≈∑ γation and expansion process✔₩&•. The study is being conducted at UCI.“Patients"₹∞ suffering with glioblasα♣toma are in great need of new, promising treat∏↔πments that might advance the curr¥γλ÷ent standard of care,” said Daniela A. Bota, MD✔φ©β, PhD, director of the UCI Health Compπ →λrehensive Brain Tumor Program, senior ass>αociate dean for clinical research, UCI Schoo↓€l of Medicine and clin®∏♥≥ical director, UCI Sue & Bill÷☆" Gross Stem Cell Research C÷±enter. “The University of Californi'δ''a, Irvine is excited to play a keyλ♣" role in research that may lead to a clini§<©×cal trial that enlists the immu↕ne system in novel ways to fight this terribl ¶±e disease.”Gliomas are the most common of the £₩malignant brain tumors. Gliε © oblastoma, the most common glioma, has a five-y♦ ear survival of less than 5 perc ∑ent. Additional treatment optionβλ>•s are urgently needed for these patients. Adopti∑ve immunotherapy is a poss≈≈☆↓ible approach for gliomas and the use ♠₩αof MILs, a cell therapy tha∞>ε•t is naturally tumor-speci♠♦fic, is one such treatment option.The bφ≠α'one marrow is a uniqueו niche in the immune system to which♣ antigen-experienced memory T cells traffi€¥←c and are then maintained. WindMIL has develoπ✔¶ped a proprietary process to select, actδivate and expand these memory T cells into MILs. ↕€ Because memory T cells in↓±♣ bone marrow occur as a result of thδ♠≥e immune system’s recognition of tumor an∏λ<εtigens, MILs are specifically suited for adopt€₽ive cellular immunotherapy and are able™↕λ≥ to directly eradicate or fac β≠ ilitate eradication of each patient’s unique ca> δ✘ncer. WindMIL is currently stud₩←ying MILs in multiple myeloma, non-small cell±☆ lung cancer and squamous cell carcin Ω↓oma of the head and neck, and plans to expand int←€₹♥o other solid tumors.“WindMIL is lookin ↑∞g forward to working with ≈Ωthe University of California, Irvine on this π<♦↓exciting project and is opt<&imistic that MILs may offer the potential t✔♠o help patients with these hard♦Ωσ-to-treat diseases,” said ™βMonil Shah, PharmD, MBA, Chief Development Of ♥φεficer at WindMIL.info♠"rmation source:pharma focus AsiaThe o± riginal link:https://www.pharmafocusasia.com/nγΩews/windmil-therapeutics-and-univers∏γity-of-california-irvine-announce-collaboraφ>∑tion-to-collect-bone-marrow-frσom-patients-with-gliomas2019 Asia-pacific♣ pharma IP Leader Summit: http://en.zensee₽ ♥£group.com/p/510934/will be held in&π nbsp;Beijing λ♥on November 14-15, and will attract mor ∑₩e than 500 industry experts±≠ from domestic and f≈>↓oreign pharmaceutical compa•≠nies, biotechnology companies, governments, asso€$ciations, law firms, intellectual pro♣"±perty agents and other companies to attend.Offici↔★al registration and consultation channels:C₽λ→ontact：AnnPhone: 021-656↕ $50305Email：Marketing@zens≥≠'eegroup.comhttp://en.zenseegroup.c∑ ♥om/p/510934/ -
1016
CRISPR Therapeutics and KSQ Therap←♥eutics Announce License Agreemen→÷t to Advance Companies’ Reσβspective Cell Therapy Programs in Oncology
CRISPR Therapeutics and KSQ Therapeuti→Ω∑λcs Announce License Agreement to Advance §✘"®Companies’ Respective Cell Therapy Programs inε₽© OncologyWEDNESDAY, OCTOBER 16, 2019CRIS★≤PR Therapeutics, a biopharmaceutical company fo&• cused on creating transformative gΩ♥©ene-based medicines for serious diseases,¶✔λ♠ and KSQ Therapeutics, a biot✔™>echnology company using CRISPR≥Ω technology to enable the company’s φ>™powerful drug discovery engine to achiπ₩αeve higher probabilities of↕£$ success in drug develo¶λ¥£pment, today announced a license agreement♥÷δ whereby CRISPR Therapeutics w÷∑$≠ill gain access to KSQ intellφδπectual property (IP) for editing certain nove™♣δl gene targets in its all€↑>ogeneic oncology cell therapy progra'•ms, and KSQ will gain access to CRI≈πSPR Therapeutics’ IP for editing novel gene targ∏£¥ ets identified by KS™♠™£Q as part of its current and future eTILT£¶€M (engineered tumor infiltrat₽♥ing lymphocyte) cell programs. The ™™ financial terms of the agreement are not bei₹₹λng disclosed.“We are thrilled to gain access✘★ ≠ to CRISPR Therapeutics☆φ>←’ foundational IP estate t€'hrough this agreement,” said David MeekΩ ♥©er, M.D., Chief Executive Officer at KSQ The₽× rapeutics. “Our eTILTM ≥δprograms involve editing∞Ω∏÷ gene targets in human TILs that were discovered•$≠§ at KSQ by applying our proprietar☆Ω★βy CRISPRomics® approach≤←$ to immune cells in multiple in vivo mode×≠ls. This agreement clears an important pat&≈h for us to be able to bring these prog×rams through development and c÷≈ ♦ommercialization, le↓←veraging CRISPR Therapeutics’ proprietar∑≤₩ y editing technology.”The gene targets w' ithin the scope of the license agreeσφ™ment were identified using KSQ’s proprietary CRIS→¶PRomics® drug discovery engine, which allowsΩ•₩∑ genome-scale, in vivo ♠≠validated, unbiased drug discovery.↓®£ These specific targets were uncov σπσered in screens to identify genetic'✘ edits that could enhance the functionality ↑£ πand quality of adoptive cell thΩλσλerapies in oncology.“KSQ ε× has built an industry-leading platform♥✔β÷ to screen for novel gene targets using♠λ its technology, and has ident↑®≈ified a group of targets that could help uπ✔nlock the full potential of adoptive cell®βπ€ therapy in oncology,” said Samarthδ∞< Kulkarni, Ph.D., Chief Executi→£☆ve Officer at CRISPR Therapeutics. “As a result ¶βof this license agreement←≠Ω≈, CRISPR Therapeutics wil↔ <♥l have the opportunity to bring these♠← novel targets into o♠☆ur leading allogeneic CAR-T development€→ platform to further strengthen our future progrδ∏ams in this important therapeutic area.”inf↑§ormation source:pharma focus As≈ ♠σiaThe original link:https:http'©s://www.pharmafocusasia.com/news/crλΩispr-therapeutics-and-ksq-therapeutics-a↔★λ nnounce-license-agreement-to-advance-compan ₹¶ ies-respective-cell-therapy-programs☆©-in-oncology2019 Asia-pacific ph€×♠§arma IP Leader Summit: ®∏http://en.zenseegroup.com/p/510934/&nb ≥αsp;will be held in Beijing on¥♦ November 14-15, and will attract more tha±¥↕n 500 industry experts from domestic'α and foreign pharmaceutical®♦ companies, biotechnology companies, govγ€☆ernments, associations, law firms, i↔λ ntellectual property agents and other ↓α↔✘companies to attend.Official regσ☆•istration and consultation channels★©←:Contact：AnnPhone: 021-65650305Email：Marketing@ze₩$±λnseegroup.comhttp://en.zen§≥≈•seegroup.com/p/510934/ -
1015
Shionogi enters into aπ× new license agreeme× πnt and research collaboration σ¶for the treatment of mycobacterial diseases wi ↔♠↕th Hsiri Therapeutics, Inc.
Shionogi enters into a new lice ®±Ωnse agreement and research collabor✘<ation for the treatment of mycobacter±→©↑ial diseases with Hsiri Th≤β©≤erapeutics, Inc.MONDAY₩↕, OCTOBER 14, 2019Shionogi & Co., Ltd≤✔. today announced that it has entered iα•→nto a new license agreement wi♦♠Ωth Hsiri Therapeutics, Inc. (Hea$∏✔d Office: Media, PA, USA; President and CEβ←O: William Claypool, M.D.; hereaf¶<ter "Hsiri") regarding a col®≤<laborative research and →↑development program to discover and develo♠×p additional novel therapeutics for non-t≠$→uberculous mycobacterial (NTM) diseases an✔↕&d tuberculosis (TB). This new collaboratio≥♣n will include techn↔'↕≈ology that complements Shionogi's σ≤σearlier collaboration arrangement wit↕ εδh Hsiri.The new technolo₽&σgy to be licensed from Hsirσ±i has a novel mechanism of action, wi←£ll be complementary to Shionog≠ i's current research with Hsiri, and i↕≠±♥s anticipated to be more effe♥≠>ctive than current therapies for mycobacterial ↓☆ ←infections. Shionogi's strengt♠ h in small molecule drug discovery and dev ★elopment in the antibacterial÷•€© area will support development of Hsir←π'i's innovative therapeutics in this coll×αaborative program. Under tπεhe terms of this agreement, Shionog≈↕®γi will have exclusive w&✘orldwide rights to develop, manufactu ≥↓re, and commercialize the compoundλ§s generated from the collaboration. Hsiri will r₽"eceive an upfront licen☆¶se fee, potential development milestone&÷s, and royalty payments based on salδ σes from Shionogi.It is r× βeported that the number of patα ↓ients suffering from NTM diseasesλ >≠ has been increasing, especially in dev ×∏eloped countries, in recent years. There is a m♥β<♦edical need to develop novel ant☆≠i-NTM drugs because of the lo¥π¥♣ng duration of treatment a♠¥✔≥nd insufficient treatment outcome ✔<♣of current therapeutics. TB is one of the three m↓∞♠₹ajor infectious diseases in the worl↑ &d, and new cases of TB are es βtimated to be 10.4 million/year. Multidrug-resist♣Ω ant TB (MDR-TB) and exte→ ¥®nsively drug-resistant TB (XDR-TB) have b€≤φecome a major public₽® health concern, and novel d£×λ₹rugs for MDR-TB and XDR-TB are anticipate ↓÷>d.Shionogi's research and development ta≤©☆•rgets infectious disease as one of its pr >€∏iority areas, and Shionogi h<$α•ave positioned "protecting pe✘©×ople from the threat ≈"of infectious diseases" as one of its social ♥₩∑mission targets. Through this cooperation, Shi<←onogi strives constantly to bring forth inno★σ$vative drugs for the treatment of in ←ε•fectious diseases, to protect the health of pat₹<>ients we serve.information&nbs¶∏p;source:pharma focus AsiaThe '₽®original link:https:https:https://www.pharmaf ↓εocusasia.com/news/shionogi-enters-into-a-φ₽new-license-agreement-and-research-≠collaboration-for-the-t• reatment-of-mycobacterial-disease€§s-with-hsiri-therapeutics-inc2019 ♣¥Asia-pacific pharma IP Lea★± ¥der Summit: http://en.zenseegrβקoup.com/p/510934/ will be held in&nφ"♣bsp;Beijing ✘γλ✔;on November 14-15, and will attract more ₽¶<φthan 500 industry expe₹₹rts from domestic and foreign pharma$₩ ¶ceutical companies, biotechnology companies, goδ↔•≠vernments, associations, law firms, in•₹>tellectual property agents and other ∑ companies to attend.Official "<'$registration and consultation channγ'εels:Contact：AnnPhone: 021-656503 05Email：Marketing@zenseegroup.comhttp:/δβπ</en.zenseegroup.com/p/5↔♠10934/ -
1014
Advaxis and UCLA Enter Collaboration for σ "γGlioblastoma Immunotherapy ₹®φ Discovery Research
Advaxis and UCLA Enter Collab∏₩oration for Glioblast€♣oma Immunotherapy Discovery ResearchFRIDAλ±₽Y, OCTOBER 11, 2019Advaxis, Inc., aα₩ clinical-stage biotec✘Ωβhnology company focused on the discovery, de∑£velopment and commercialization of i₩mmunotherapy products, today ✔₹αannounced a research c✔ ©ollaboration agreement with the Universit∏<ε↑y of California Los Angele φs (UCLA) to conduct preclini♠∑←cal studies evaluating theφα Company’s Lm technology in mouse tumor mo↓$dels of glioblastoma∞< multiforme (GBM). Specifically, the collabo<™ration with Dr. Vaithi Aruπ§mugaswami’s group at UCLA’s Department of λMolecular and Medical Pharmacology will i>'∞nvestigate anti-tumor☆σ immunity and anti-tumo¥±•×r responses generated by Lm vaccines that ex↓∑press diverse glioblastoma neoantigens.“We are→₹ excited that Dr. Arumugaswami and his colleagβ'ues at UCLA will investigat±Ωe the potential of our Lm technology platform in >♥GBM, one of the deadliest cancer∑δs,” said Andres Gutierrez, Executive Vice Preside→ nt and Chief Medical Officer of Advaxis. ↕↕“Contrary to other t&©©↓umor types, GBM has not seen m®♥¶uch success in targeting by immunotherapeutic ♣σλ₹agents due to a low tumor m ₩ >utation burden, high tumor heterogen✘∏πeity and presence of the blood brain ↔↓≤barrier, among other₹™ factors. Hence, Dr. Arumugasw€δ÷✔ami’s characterization of the ne↕☆oantigen landscape aφσnd immune responses to Lm- constr±ucts may lead to the development of novel th×→ "erapies with clinical activity in thα$≤₹is elusive cancer.”information source:p×↓"≈harma focus AsiaThe original link:htt☆€→ps:https:https://www.pharmafocusas♥∞∞δia.com/news/advaxis-and-ucla-enter-co€'llaboration-for-glioblastoma-immunotherap∞↕y-discovery-research2019 Asia-pacific pha ≠rma IP Leader Summit: htt∞p://en.zenseegroup.com/λ•p/510934/will be held in Beijing γ♠₹≈ on November 14-σ ≈♦15, and will attract more t©•han 500 industry experts fromα★ domestic and foreign pharmaceutical companies, b♠$iotechnology companies, gove§≠♠rnments, associations, law firms, i×δ∏σntellectual property agents§¥α and other companies to attend★€δ .Official registration and <₹consultation channels:Contact：AnnPhone: 021-65650₽✘305Email：Marketing@zenseeg<₽↓roup.comhttp://en.zenseegroup.com/p/510934/ -
1011
Viela Bio Enters Str£"ategic Collaboration with Ω∏Mitsubishi Tanabe Pharma ♦∞ ₽to Develop and Commercialize Inebilizu" 'mab for Autoimmune Diseases in Ja≤σ<pan and Other Asia Regions
THURSDAY, OCTOBER 10, 2019Viela •≠ Bio, Inc. and Mitsubishi Tanabe↑β← Pharma Corporation (“MTPC”) today announced a c&∏λ¶ollaboration focused on the development and$±¥♥ commercialization o✔←γf inebilizumab – Viela’s hum÷λanized anti-CD19 monoclonal antibody£ – in nine Asia regions for neuromyelitis optic₽↕a spectrum disorder (NMOSD), as well as≈σ↓Ω other potential futuεre indications.“This partnership adds to ∏≤₩our ability to commercialize i$✘↕"nebilizumab globally, subject tπ₽o regulatory approval,” commented Bing ✔≤Yao, Ph.D., Viela’s Executive C&λhairman and Chief Executive Offi ε&cer. “As a well-established pharmace♦♠utical company in Japan, Mitsubishi Tana<÷be has strong product development and commerc∞φ©λialization capabilities in Asia, and w≤ <e believe, is an ideal par₩$tner for expanding inebilizumab’₹∑≤λs potential reach to t¶>$€housands of additional patients in ne×∑ed of viable treatments, with NMOSD as an σ₽ initial indication.”Under te¥₩ rms of the collaboration, Viela will receive an¶≥ up-front licensing fee of $30 million as wπ∑ell as additional paymen≥≤ts contingent on certain development and♣₹πλ commercial milestones, plus paym≠'ents based, in part, on sales revenue. φ<MTPC will be responsible for leading ©©© development and commerc ↕&ialization of inebilizumab in Japan•ε≤, Thailand, South Korea, Ind•✘onesia, Vietnam, Malaysia, Philippi÷♣nes, Singapore, and Taiwan.“Our organization i✘¥γs delighted to partner with Viela to developφαε and commercialize their promising p≠' $roduct candidate inebilizumab f∞or autoimmune and inflammatory diseases,” said Masayuki Mitπ₩§♠suka, MTPC President & Represen±§ tative Director. “Inebilizumab is an εφexciting product candidate tha¶πt, based on the results from the N-MOmentuΩ< m pivotal study, is w≈₽≤•ell-positioned to provide meaningful →'benefit for patients with NMOSD, and poten ↕tially additional diseases, subject to reg>≈ulatory approval. We are excit↑♥→ed to work with Viela to ≠advance inebilizumab in Japan and o₽♠∏ther Asia regions, and look foשrward to a productive partnership between our com∑→panies.”The U.S. Food and Drug ↕©€★Administration (FDA) recently acce≠∏pted for review Viela’s Biolog¥₽✔✘ics License Application &£(BLA) for inebilizumab ♣↔π±for the treatment of NMOSD. information$•" source:pharma focus A ☆siaThe original link:httpδ±>s:https://www.pharmafo cusasia.com/news/viela-bio-enters-strategic-coll∞♠↔aboration-with-mitsubishi-≤↕tanabe-pharma-to-develop-and-commercialize✘-inebilizumab-for-autoγ$immune-diseases-in-japan-and-other-★™asia-regions2019 Asia-pa♣♥÷cific pharma IP Leader Summit: http://en.z↔↑✘enseegroup.com/p/510934/will be held i ✔♦n Beijing on November₩< 14-15, and will attract more than 50∑≈★✘0 industry experts from domestic and foreign phar↕αmaceutical companies, biotechnology compan♣£®ies, governments, associations, law firms, ←♣ ≈intellectual property agents and othe>✔₽γr companies to attend.Official registrat'♦ion and consultation c'€hannels:Contact：AnnPhone: 021-65®>'650305Email：Marketing@zenseegroup.☆♥✘comhttp://en.zenseegroup.com/p•©'/510934/
Contact Us
Zensee_Daystar online
© 2011-2016